Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($1.27), $0.13 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $4.66 million.

Cash, cash equivalents and marketable securities, excluding restricted cash, totaled $498.3 million as of June 30, 2017.

2017 Financial Guidance

The Company is revising its guidance for operating loss excluding non-cash share-based compensation for the full-year of 2017 to a range of $205.0 million to $215.0 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.